IL6 and COVID-19: This is of particular interest as clinical trials, including REMAP-CAP demonstrated improved outcomes and survival in patients treated with IL-6 antagonists, whereas others such as COVACTA were less conclusive.49,50 The fact that combinatorial blockade resulted in significant cardiomyocyte rescue in our study, warrants studying this in a clinical trial and raises the question whether patients severely ill with COVID-19 and a myocardial injury should be treated more aggressively.